



ACN 103 782 378

3 November 2021

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000
Attention: Oma Murad
By email only: oma.murad@asx.com.au

Dear Madam,

SECTION 708A CLEANSING NOTICE

This notice is given by Zelira Therapeutics Ltd (**Zelira or the Company**) (ASX: ZLD) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

1. On 3 November 2021, the Company issued 79,908,676 Shares at an issue price of \$0.06 (6 cents) per Share to Quincy Street Capital LLC, a US-based family office fund, to raise \$4,794,521, with no fees payable on the placement, pursuant to the capital raising announced to ASX on 20 October 2021;
2. On 3 November 2021, the Company issued 6,000,000 Shares at an issue price of \$0.03125 (3.125 cents) per Share to unlisted option holder, to raise \$187,500, pursuant to the exercise of unlisted options, issued on 17 November 2016 and, exercisable at \$0.03125 per Share on or before 17 November 2021; and
3. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
4. The Company is providing this notice under section 708A(5)(e) of the Corporations Act;
5. As at the date of this notice Zelira Therapeutics has complied with:
 - a. The provisions of Chapter 2M of the Corporations Act as they apply to Company; and
 - b. Section 674 of the Corporations Act; and
6. As at the date of this notice, there is no information that is “excluded information” (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by Zelira.

Please see the attached Appendix 2A for details of the share issue.

This announcement has been authorized by the Board of the Company.

Yours sincerely

Tim Slate
Company Secretary

